TY - JOUR
T1 - New insight into immunity and immunopathology of Rickettsial diseases
AU - Mansueto, Pasquale
AU - Vitale, Giustina
AU - Cascio, Antonio
AU - Seidita, Aurelio
AU - Pepe, Ilenia
AU - Carroccio, Antonio
AU - Di Rosa, Salvatore
AU - Rini, Giovam Battista
AU - Cillari, Enrico
AU - Walker, David H.
PY - 2012
Y1 - 2012
N2 - Human rickettsial diseases comprise a variety of clinical entities caused by microorganisms belonging to the genera Rickettsia, Orientia, Ehrlichia, and Anaplasma. These microorganisms are characterized by a strictly intracellular location which has, for long, impaired their detailed study. In this paper, the critical steps taken by these microorganisms to play their pathogenic roles are discussed in detail on the basis of recent advances in our understanding of molecular Rickettsia-host interactions, preferential target cells, virulence mechanisms, three-dimensional structures of bacteria effector proteins, upstream signalling pathways and signal transduction systems, and modulation of gene expression. The roles of innate and adaptive immune responses are discussed, and potential new targets for therapies to block host-pathogen interactions and pathogen virulence mechanisms are considered.
AB - Human rickettsial diseases comprise a variety of clinical entities caused by microorganisms belonging to the genera Rickettsia, Orientia, Ehrlichia, and Anaplasma. These microorganisms are characterized by a strictly intracellular location which has, for long, impaired their detailed study. In this paper, the critical steps taken by these microorganisms to play their pathogenic roles are discussed in detail on the basis of recent advances in our understanding of molecular Rickettsia-host interactions, preferential target cells, virulence mechanisms, three-dimensional structures of bacteria effector proteins, upstream signalling pathways and signal transduction systems, and modulation of gene expression. The roles of innate and adaptive immune responses are discussed, and potential new targets for therapies to block host-pathogen interactions and pathogen virulence mechanisms are considered.
UR - http://www.scopus.com/inward/record.url?scp=81555221702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81555221702&partnerID=8YFLogxK
U2 - 10.1155/2012/967852
DO - 10.1155/2012/967852
M3 - Review article
C2 - 21912565
AN - SCOPUS:81555221702
SN - 1740-2522
VL - 2012
JO - Clinical and Developmental Immunology
JF - Clinical and Developmental Immunology
M1 - 967852
ER -